Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Axon Enterprise Inc (AXON) vs Centene Corp (CNC) Price & Performance

Axon Enterprise IncTrade
Centene CorpTrade

Price performance (Past 24H)

Key statistics

Axon Enterprise Inc vs Centene Corp — how do they compare? Axon Enterprise Inc trades at $609.7 (market cap $51.69B), while Centene Corp trades at $66.57 (market cap $32.05B). The key difference: Axon Enterprise Inc is the larger of the two by market cap, and Centene Corp is trading nearer its 52-week high, Axon Enterprise Inc nearer its low. Which is the better fit depends on your goals.

AXONCNC
Market Cap
$51.69B$32.05B
Sector
TechnologyHealth
52-Week High
$791.62$68.72
52-Week Low
$345.94$26.17
Enterprise Value
$52.83B$21.10B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Axon Enterprise Inc

Axon Enterprise (AXON) trades at $616.97, up 3.46% in the last 24 hours, showing strong momentum with a bullish technical signal and consistent earnings beats. The stock is near its pivot point of $629, with support at $616 and resistance at $649. Revenue grew 35% year-over-year in Q2 2026, driven by AI and counter-drone offerings, though high valuation multiples like a P/E of 265.13 and P/S of 16.35 reflect premium pricing. Analyst consensus is strongly bullish with an $685 price target, but gross margin compression and elevated multiples pose risks.

Outlook remains positive given robust growth and AI adoption, but investors face valuation risks and margin pressures. The stock offers upside to consensus targets if execution continues, yet any growth slowdown could trigger significant multiple contraction. Key catalysts include Q3 2026 earnings and AI-driven contract expansions.

Centene Corp

Centene (CNC) trades at $66.56, up 1.2% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $71.00. The company reported strong Q2 2026 earnings of $2.51 per share, beating estimates, and raised its full-year EPS guidance, reflecting margin recovery and cost discipline. Revenue growth remains robust, projected to reach $202.9 billion in 2026, though net income margins are negative due to elevated medical costs.

The stock presents a value opportunity with low P/E (8.06) and P/S (0.16) ratios, but investors face risks from Medicaid membership volatility and regulatory pressures. Analyst sentiment is strongly bullish (61% buy ratings), with institutional interest growing, as seen in recent fund additions. Near-term upside is likely if cost controls sustain profitability improvements.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Axon Enterprise Inc

Axon develops technology and weapons for law enforcement and military use. Its ecosystem includes TASER devices, body cameras, and Evidence.com, a cloud-based platform for digital evidence management.

Read more on AXON

About Centene Corp

Centene is a managed-care organization focused on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 22 million medical members as of September 2021, mostly in Medicaid (68% of membership), the individual exchanges (10%), Medicare Advantage (6%), and the balance in Tricare (West region), correctional facility, and international plans. The company also serves 4 million users through the Medicare Part D pharmaceutical program.

Read more on CNC